Fig. 1From: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsClinical case: positron emission tomography results pre- (a) and post-therapy (b)Back to article page